Navidea Biopharmaceuticals Reports First Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Navidea Biopharma (NAVB) Reports Q1 Loss of $0.13
May 14, 2020 4:25 PM EDTNavidea Biopharma (NYSE: NAVB) reported Q1 EPS of ($0.13), versus ($0.24) reported last year. Revenue for the quarter came in at $155.66 thousand, versus $41.62 thousand reported last year.
First Quarter 2020 Highlights and Subsequent Events
Continued with double-digit subject enrollment in the Companys NAV3-31 Phase 2b study in rheumatoid arthritis (RA) and completed enrollment of subjects in Arms 1 and 2.Continued enrollment in the Investigator Initiated Phase 2 trial being run at the Massachusetts General Hospital evaluating Tc99m tilmanocept uptake in atherosclerotic plaques of HIV-infected individuals.Announced extension by the U.S. Patent and... More